Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05765253 · ClinicalTrials.gov registry record · NA
Achieving Portal Access With Scorpion Post-Approval Study (APASS)
A NA study, sponsored by Argon Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT05765253: Clinical Trial NA study, sponsored by Argon Medical Devices.
NCT05765253 is a NA study that was terminated before completion, run by Argon Medical Devices. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05765253, a NA study, was terminated before completion, sponsored by Argon Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.
Primary Outcome
Creation of the parenchymal tract between the hepatic vein and an intrahepatic branch of the portal vein confirmed by portogram (CO2/contrast).
Interventions
- PROCEDURE Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- DEVICE Scorpion Portal Vein Access Kit
- DEVICE Cook Transjugular Liver Access Set
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2023-07-13 |
| Est. Completion | 2023-11-19 |
| Phase | NA |
Why NCT05765253 stopped before completion
NCT05765253 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 3 interventions - of which Transjugular Intrahepatic Portosystemic Shunt (TIPS) is the first listed.
NCT05765253 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05765253 about?
NCT05765253 is a clinical study titled "Achieving Portal Access With Scorpion Post-Approval Study (APASS)". Creation of the parenchymal tract between the portal vein and the hepatic vein is the most difficult and time consuming step in a TIPS procedure. The purpose of this study is to evaluate portal vein access sets during the TIPS procedure.
What is the current status of trial NCT05765253?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2023-07-13. Estimated completion is 2023-11-19.
What interventions are being tested in trial NCT05765253?
The interventions under investigation include: Transjugular Intrahepatic Portosystemic Shunt (TIPS) (PROCEDURE), Scorpion Portal Vein Access Kit (DEVICE), Cook Transjugular Liver Access Set (DEVICE).
Who is sponsoring clinical trial NCT05765253?
This trial is sponsored by Argon Medical Devices, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05765253's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI